$ cat jobs/sales-director-nucs-ai-1fc3ba873939.json
Sales Director
About Nucs AI Nucs AI is revolutionizing cancer care through cutting-edge AI and medical imaging technology. Founded in 2024 by a multidisciplinary team of oncologists, AI researchers, and healthcare innovators, we’re tackling one of medicine’s most pressing challenges: the growing demand for accurate, timely cancer diagnostics in the face of rising scan volumes and limited radiologist capacity. We sit at the intersection of diagnostics and treatment planning—building AI-powered tools at the convergence of medical imaging, radioligand therapy, and artificial intelligence. Starting with prostate cancer and expanding across oncology, we partner with world-leading medical institutions and pharmaceutical companies across the US, Europe, and Australia to bring precision oncology into everyday clinical practice. Our mission is to enhance diagnostic precision and expand access to expert-level cancer care, improving patient outcomes worldwide. We’re venture-backed, early-stage, and building a team that blends deep clinical expertise with engineering intensity—moving with the rigor the medical field demands and the speed the problem deserves. The Opportunity Nucs AI is entering a pivotal phase—our products are being validated in clinical settings, partnerships are accelerating, and we’re preparing for commercial launch. This role is for someone who can build our go-to-market engine from the ground up, leveraging deep existing relationships across medical imaging, nuclear medicine, radioligand therapy, and AI-driven healthcare. This is a foundational commercial hire. You’ll own the full sales cycle across a wide range of deal sizes and customer types—from closing focused product deployments with independent imaging centers to securing large-scale enterprise agreements with pharmaceutical companies and hospital networks. You bring a multilayered sales approach and understand that the motion for a $100K imaging center deal is fundamentally different from a multi-year pharma col